Table 4.
Events
| Outcomes | N (%) |
|---|---|
| Follow-up duration (months)a (%) | |
| Mean (SD) | 69 (34) |
| Median (IQR) | 65 (42–93) |
| Vital status (number of patients) (%) | |
| Alive | 2033 (90.9) |
| Dead | 204 (9.4) |
| Death without BF | 172 |
| ≤24 months | 33 |
| >24 months | 139 |
| Death after BF | 32 |
| ≤24 months | 1 |
| >24 months | 31 |
| Of whom owing to prostatic cancer | 26 |
| BF (number of patients) (%) | |
| No | 2030 (90.7) |
| Yes | 207 (9.3) |
| Alive at the last follow-up | 175 |
| Death after BF | 32 |
| Time to BF (months)a | |
| N | 207 |
| Mean (SD) | 48 (29) |
| Median (IQR) | 42 (24–64) |
BF, biochemical failure; IQR, interquartile range; SD, standard deviation.
a
From date of low-dose-rate brachytherapy implantation.